Cargando…

Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers

ALK, ROS1, and RET kinase fusions are important predictive biomarkers of tyrosine kinase inhibitors (TKIs) in non‐small‐cell lung cancer (NSCLC). Analysis of cell‐free DNA (cfDNA) provides a noninvasive method to identify gene changes in tumor cells. The present study sought to use cfRNA and cfDNA f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hasegawa, Nobuhiko, Kohsaka, Shinji, Kurokawa, Kana, Shinno, Yuki, Takeda Nakamura, Ikuko, Ueno, Toshihide, Kojima, Shinya, Kawazu, Masahito, Suehara, Yoshiyuki, Ishijima, Muneaki, Goto, Yasushi, Kojima, Yuki, Yonemori, Kan, Hayashi, Takuo, Saito, Tsuyoshi, Shukuya, Takehito, Takahashi, Fumiyuki, Takahashi, Kazuhisa, Mano, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486187/ https://www.ncbi.nlm.nih.gov/pubmed/34310819 http://dx.doi.org/10.1111/cas.15084

Ejemplares similares

Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single‐cell level
por: Nakamura, Ikuko Takeda, et al.
Publicado: (2021)

Detection of circulating sarcoma tumor cells using a microfluidic chip-type cell sorter
por: Hasegawa, Nobuhiko, et al.
Publicado: (2019)

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
por: Hayakawa, Daisuke, et al.
Publicado: (2019)

Transcription start site‐level expression of thyroid transcription factor 1 isoforms in lung adenocarcinoma and its clinicopathological significance
por: Sano, Kei, et al.
Publicado: (2021)

Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines
por: Xu, Shiting, et al.
Publicado: (2023)

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
por: Shimamura, Shoko Sonobe, et al.
Publicado: (2022)

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
por: Nakamura, Ikuko Takeda, et al.
Publicado: (2021)

CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma
por: Kanamori, Koichiro, et al.
Publicado: (2023)

Nanostring-based screening for tyrosine kinase fusions in inflammatory myofibroblastic tumors
por: Kurihara, Taisei, et al.
Publicado: (2020)

Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-κB-activating potential
por: Yamato, Azusa, et al.
Publicado: (2015)

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer
por: Kurokawa, Kana, et al.
Publicado: (2022)

Successful restart of chemotherapy in a patient with primary mediastinal nonseminomatous germ cell tumor after COVID‐19 infection
por: Tanabe, Yuki, et al.
Publicado: (2022)

Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer
por: Yamaguchi, Hiroyuki, et al.
Publicado: (2015)

Exploration of predictive biomarkers for postoperative recurrence of stage II/III colorectal cancer using genomic sequencing
por: Kishigami, Fumishi, et al.
Publicado: (2022)

Establishment of Rapid and Accurate Screening System for Molecular Target Therapy of Osteosarcoma
por: Sasa, Keita, et al.
Publicado: (2022)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
por: Xu, Shiting, et al.
Publicado: (2022)

Genomic profiles of colorectal carcinoma with liver metastases and newly identified fusion genes
por: Oga, Takafumi, et al.
Publicado: (2019)

Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report
por: Ueda, Shoko, et al.
Publicado: (2021)

Retraction Note to: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
por: Sasa, Keita, et al.
Publicado: (2022)

RETRACTED ARTICLE: IRE1α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
por: Sasa, Keita, et al.
Publicado: (2021)

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study
por: Kurokawa, Kana, et al.
Publicado: (2022)

Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma
por: Ishii, Midori, et al.
Publicado: (2018)

Cerebral infarction in advanced non-small cell lung cancer: a case control study
por: Kato, Motoyasu, et al.
Publicado: (2016)

Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin‐fixed paraffin‐embedded specimens
por: Kohsaka, Shinji, et al.
Publicado: (2019)

Differential regulation of CpG island methylation within divergent and unidirectional promoters in colorectal cancer
por: Namba, Shinichi, et al.
Publicado: (2019)

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2019)

Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2020)

Inactivating mutations and hypermethylation of the NKX2‐1/TTF‐1 gene in non‐terminal respiratory unit‐type lung adenocarcinomas
por: Matsubara, Daisuke, et al.
Publicado: (2017)

Identification of candidates for driver oncogenes in scirrhous‐type gastric cancer cell lines
por: Sai, Eirin, et al.
Publicado: (2019)

ACT-1 Multicenter investigator-initiated registration-directed Phase 2 study of E7090 in subjects with advanced or recurrent solid tumors with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
por: Takahashi, Masamichi, et al.
Publicado: (2021)

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
por: Kato, Motoyasu, et al.
Publicado: (2014)

Strategic Approach to Heterogeneity Analysis of Cutaneous Adnexal Carcinomas Using Computational Pathology and Genomics
por: Nishimura, Yuuki, et al.
Publicado: (2023)

Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib
por: Nurwidya, Fariz, et al.
Publicado: (2021)

PPP2R1A regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma
por: Akaike, Keisuke, et al.
Publicado: (2018)

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
por: Chiba, Yohei, et al.
Publicado: (2022)

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study
por: Nakamura, Kota, et al.
Publicado: (2017)

Transcript-targeted analysis reveals isoform alterations and double-hop fusions in breast cancer
por: Namba, Shinichi, et al.
Publicado: (2021)

Generating Potential Protein-Protein Interaction Inhibitor Molecules Based on Physicochemical Properties
por: Ohue, Masahito, et al.
Publicado: (2023)

KRAS mutations in uterine endometrium are associated with gravidity and parity
por: Inoue, Satoshi, et al.
Publicado: (2020)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v2sbamt9rm7j5bb7mbmba2423g